Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study

BACKGROUND: Inhibition of the epithelial sodium channel (ENaC) in cystic fibrosis (CF) airways provides a mutation-agnostic approach that could improve mucociliary clearance in all CF patients. BI 1265162 is an ENaC inhibitor with demonstrated pre-clinical efficacy and safety already demonstrated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Goss, Christopher H., Fajac, Isabelle, Jain, Raksha, Seibold, Wolfgang, Gupta, Abhya, Hsu, Ming-Chi, Sutharsan, Sivagurunathan, Davies, Jane C., Mall, Marcus A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850685/
https://www.ncbi.nlm.nih.gov/pubmed/34385272
http://dx.doi.org/10.1183/13993003.00746-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850685/
https://www.ncbi.nlm.nih.gov/pubmed/34385272
http://dx.doi.org/10.1183/13993003.00746-2021

Ejemplares similares